Scancell to give AACR presentation on SCIB1 vaccine

Scancell is to present interim data on their SCIB1 vaccine at this month's Annual Meeting of the American Association for Cancer Research (AACR), held in San Diego.  The event kicks off tomorrow and runs until April 9th.  Scancell will give their presentation on  Tuesday, Apr 8th, between 1:35 PM - 1:50 PM.

AACR is the premier cancer research event with about 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world scheduled to be in attendance. It provides a unique opportunity for members of the worldwide cancer research community to learn about cutting-edge advances, obtain feedback on their own research, and make connections that will foster future collaborations.

Comment by the British blogger Shri9: 
"If you follow the industry news on a regular basis you can't fail to read how Scancell''s American competitors enthuse on their websites and in the press that they are to present their trial results at the AACR Annual Meeting. This appears to be a must that so many European and overseas companies get excluded from. Scancell's invitation to present their SCIB1 vaccine's trial results at the AACR ensures a level playing field with regard to the company's promotion in the world's most important oncology market. It is also an important reminder that one of Scancell's most important collaborators on their SCIB1 vaccine is the United States government whose Institutes of Health is to receive royalty payments when the vaccine enters production. Earlier this year the U S Food and Drug Administration (FDA) granted orphan drug designation to SCIB1 qualifying the vaccine for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and at least seven-year market exclusivity following drug approval by the FDA."

Here is a link to an abstract of the upcoming presentation:
http://www.abstractsonline.com/Plan/ViewAbstr...6874D93%7D

S ource :
http://www.hotstockmarket.com/t/277760/scnlf-...st_3031506